Clinical trials: Acute Moderate-to-severe Pain
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
COVID19 ARDS
Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome
Mesenchymal stem cells (MSCs) are of potential help in acute respiratory distress syndrome (ARDS), due to their anti-inflammatory properties.
- Trial name
- MSC-COVID19 (NCT04625738)
- Testing
- Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
Acute Pancreatitis, Severe Acute Pancreatitis
Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis
This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.
- Trial name
- NCT07153809
- Testing
- FMT
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Changhai Hospital
Acute Pancreatitis
Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)
This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of…
- Trial name
- AT-PROPANC (NCT02373293)
- Where
- 2 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Francisco Javier García Borobia
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
Acute Respiratory Distress Syndrome
Artificial Increase in Chest Wall Elastance as an Alternative to Prone Positioning in Moderate-to-severe ARDS.
During moderate to severe ARDS, sessions of prone positioning lead to lung and chest wall mechanics changes that modify regional ventilation, with a final redistribution of tidal volume and PEEP towards dependent lung regions…
- Trial name
- ALTERPRONE (NCT03719937)
- Testing
- weight on the anterior chest of the patient
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Catholic University of the Sacred Heart
Acute Viral Bronchiolitis
Prone Position in Acute Bronchiolitis
Acute viral bronchiolitis is the leading cause of community-acquired acute respiratory failure in developed countries (20 000 to 30 000 hospitalizations each year in France).
- Trial name
- PROPOSITIS (NCT03976895)
- Testing
- Supine position (SP), Prone position (PP)
- Where
- 16 sites in France
- Volunteers
- 452 people
- Sponsor
- Hospices Civils de Lyon
Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression.
- Trial name
- NCT04389944
- Testing
- convalescent plasma application to SARS-CoV-2 infected patients
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Arthritis, Gouty
Celebrex In Acute Gouty Arthritis Study
This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation…
- Trial name
- NCT00549549
- Testing
- Indomethacin, Celecoxib
- Where
- 81 sites in United States, Canada and 10 more
- Volunteers
- 402 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Ischemic Stroke
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
- Trial name
- C-REGS2 (NCT03480698)
- Testing
- Cerebrolysin
- Where
- 8 sites in Austria
- Volunteers
- 1,851 people
- Sponsor
- Ever Neuro Pharma GmbH
Covid-19
Antioxidant Therapy for COVID-19 Study
Finding effective strategies to treat or prevent the novel coronavirus disease that started in 2019 (COVID-19) is a global public health priority.
- Trial name
- GSHSOD-COVID (NCT04466657)
- Testing
- Antioxidation Therapy, Standard of Care
- Where
- 11 sites in Nigeria
- Sponsor
- Obafemi Awolowo University
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
SARS-CoV-2 Infection
Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient
Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.
- Trial name
- COVID-19 (NCT04595136)
- Testing
- Drug COVID19-0001-USR, normal saline
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- United Medical Specialties
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Interstitial Cystitis, Bladder Pain Syndrome
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study…
- Trial name
- NCT06394830
- Testing
- VNX001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaneltix Pharma, Inc.
COVID-19, SARS-CoV-2 Infection
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19
- Conditions
- COVID-19, SARS-CoV-2 Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NCT04516811
- Testing
- COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
- Where
- 2 sites in South Africa
- Volunteers
- 102 people
- Sponsor
- South African National Blood Service
Acute Respiratory Distress Syndrome, Hypercapnia
Correction by ECCO2-R of Hypercapnia in Patients With DVP in Moderate to Severe ARDS Under Protective Ventilation.
Pulmonary vascular dysfunction (DVP) is associated with a pejorative prognosis during ARDS. There is no specific therapeutic intervention to thwart it.
- Trial name
- COVAP (NCT03303807)
- Testing
- Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Pain
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
- Trial name
- ALLEVIATE1 (NCT06545097)
- Testing
- Cebranopadol 400 ug, Cebranopadol 200 ug
- Where
- 4 sites in United States
- Volunteers
- 279 people
- Sponsor
- Tris Pharma, Inc.
Acute Moderate-to-severe Pain
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60…
- Trial name
- NCT02662556
- Testing
- sufentanil sublingual tablet 30 mcg
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Talphera, Inc
Candidiasis, Vulvovaginal, Mycoses
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
The purpose of this study is to determine if two topical formulations of CD101 are safe and effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC) compared to oral fluconazole.
- Conditions
- Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal
- Trial name
- NCT02733432
- Testing
- CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%)
- Where
- 24 sites in United States
- Volunteers
- 126 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)